Practical aspects of insulin pen devices

Journal of Diabetes Science and Technology

Volumn 4, Issue 3, 2010, Pages 522-531

  Pearson, Teresa L ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Diabetes; Insulin; Insulin pen; Practical use

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

DIABETES MELLITUS; DRUG SELF ADMINISTRATION; HUMAN; INSTRUMENTATION; METHODOLOGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; SELF ADMINISTRATION;

EID: 78349260526     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400304     Document Type: Conference Paper

References (74)

1. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-62. (Pubitemid 46986681)
2. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-25; discussion 1710-1.
3. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-48. (Pubitemid 37510593)
4. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43(1):69-74. (Pubitemid 38112268)
5. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22(1):137-40. (Pubitemid 29028310)
6. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-96. (Pubitemid 28343501)
7. Kadiri A, Chraibi A, Marouan F, Ababou MR, el Guermai N, Adjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract. 1998;41(1):15-23. (Pubitemid 28394280)
8. Da Costa S, Brackenridge B, Hicks D. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28(1):52-6, 59-60.
9. Bhargava A. Insulin therapy: the question this issue. Insulin. 2007;2(2):92-4.
10. Marcus A. Diabetes care: insulin delivery in a changing world. Medscape J Med. 2008;10(5):120.
11. Magnotti MA, Rayfield EJ. An update on insulin injection devices. Insulin. 2007;2(4):173-81. (Pubitemid 350131533)
12. Pawaskar MD, Camacho FT, Andersen RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29 Spec No:1294-305. (Pubitemid 351172225)
13. Novo Nordisk (2010) FlexPen insulin pen [cited 2010 Mar 23]. Available from: http://www.novonordiskcare.com/flexpen/.
14. Medicare: the official US government site for people with Medicare July 9, 2009 [cited 2009 Sept 16]. Available from: http://formularyfinder.medicare. gov/formularyfinder.
15. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3):430-2.
16. Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract. 2007;13(6):672-8.
17. Peyrot M, Rubin RR, Lauritzen T, Skovlund S, Snok FJ, Matthews DR, Landgraf R, Kleinebreil L; International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-9. (Pubitemid 43951158)
18. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-505. (Pubitemid 39572159)
19. Sommavilla B, Jorgensen C, Jensen K. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2223-32.
20. Lee IT, Liu HC, Liau YJ, Lee WJ, Huang CN, Sheu WH. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract. 2009;15(4):699-703.
21. Hörnquist JO, Wikby A, Andersson PO, Dufva AM. Insulin-pen treatment, quality of life and metabolic control: retrospective intragroup evaluations. Diabetes Res Clin Pract. 1990;10(3):221-30.
22. Davis EM, Bebee A, Crawford L, Destache C. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ. 2009;35(5):799-809.
23. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195-201.
24. Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347-57.
25. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789-98.
26. Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4(3):xxx-xxx.
27. Eli Lilly (2006) HumaPen LUXURA HD insulin delivery device user manual (November 11, 2006).
28. Eli Lilly (2006) HumaPen MEMOIR user manual (revised November 20, 2006).
29. Eli Lilly (2007) KwikPen disposable insulin delivery device user manual (September 6, 2007).
30. Eli Lilly (2009) Insulin pens [cited 2009 Jul 31]. Available from: http://www.humalog.com/humalog-insulin-pens/humalog-insulin-pens.jsp.
31. Eli Lilly (2009) Prefilled insulin delivery device user manual (revised April 17, 2009).
32. Novo Nordisk (1998) NovoPen 3 instructions for use.
33. Novo Nordisk (2002) NovoPen Junior instructions for use.
34. Novo Nordisk (2006) NovoLog Mix 70/30 FlexPen simple instructions for use (September 2006).
35. Novo Nordisk (2009) Insulin pens [cited 2009 Jul 31]. Available from: http://www.novonordiskcare.com/insulin-pens.
36. Novo Nordisk (2009) NovoLog Mix 70/30 FlexPen [cited 2009 Jul 31]. Available from: http://www.novologmix70-30.com/novolog-mix-FlexPen.asp.
37. Novo Nordisk (2009) NovoLog FlexPen [cited 2009 Jul 31]. Available from: http://www.novolog.com/devices-flexpen.asp?s=ds&h=150.
38. Novo Nordisk (2009) Levemir FlexPen [cited 2009 Jul 31]. Available from: http://www.levemir-us.com/about-levemir-FlexPen-demo.asp?WT.ac=LevemirFlexPen.
39. Owen Mumford (2006) Autopen 24 instructions for use (revised April 2006).
40. Owen Mumford (2009) Autopen [cited 2009 Jul 31]. Available from: http://www.owenmumford.com/us/range/24/autopen.html.
41. Sanofi-Aventis (2009) Lantus SoloSTAR pen [cited 2009 Jul 31]. Available from: http://www.lantus.com/solostar/solostar-insulin-pen.aspx.
42. Sanofi-Aventis (2009) Your guide to the Lantus SoloStar pen.
43. Sanofi-Aventis (2009) OptiClik [cited 2009 Jul 31]. Available from: http://www.opticlik.com/.
44. BD (2009) BD pen needles fit these pens [cited 2009 Jul 31]. Available from: http://www.bd.com/us/diabetes/page.aspx?cat=7002&id=10257.
45. American Diabetes Association. 2009 resource guide. Diabetes Forecast. 2009;62.
46. Lautier O, Mosnier-Pudar H, Durain D, Gonbert S, Spinu L, Faure P. Risk of needlestick injuries among nurses using NovoFine Autocover safety needles and nurses' satisfaction with the needles: the NOVAC study. Insulin. 2008;3(4):232-7.
47. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A. Patient and physician satisfaction with the Humulin/Humalog pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther. 2000;22(9):1049-67.
48. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27 Suppl B:S89-100.
49. US Food and Drug Administration. Risk of transmission of blood-borne pathogens from shared use of insulin pens. Information for healthcare professionals. March 19, 2009 [cited 2009 Jul 31]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm133352.htm.
50. Bhardwaj VR, Metcalfe N, Innes E, Harrison E, Jenkins D. Recurrent diabetic ketoacidosis after changing pen devices for insulin injection. BMJ. 2006;332(7552):1259-60. (Pubitemid 44365419)
51. Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36-8.
52. Diglas J, Feinböck C, Irsigler K, Winkler F, Egger T, Weitgasser R, Pieber T, Lytzen, L. Reduced pain perception with Pen Mate, an automatic needle insertion device for use with an insulin pen. Practical Diabetes Int. 1999;16(2):39-41. (Pubitemid 29229578)
53. Boronat M, García-Delgado Y, Pérez-Martin N, Nóvoa FJ. Severe deterioration of metabolic control caused by malfunction of a disposable insulin pen device. J Am Board Fam Med. 2008;21(6):575-6.
54. Venekamp WJ, Kerr L, Dowsett SA, Johnson PA, Wimberley D, McKenzie C, Malone J, Milicevic Z. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 2006;22(2):315-25. (Pubitemid 44296755)
55. Shaefer CF. The pen is mightier than the sword. Insulin. 2009;4(3):132-5.
56. Asakura T, Seino H, Kageyama M, Yohkoh N. Evaluation of injection force of three insulin delivery pens. Expert Opin Pharmacother. 2009;10(9):1389-93.
57. Pfützner A, Reimer T, Hohberg C, Frøkjaer LP, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-9.
58. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther. 2005;7(4):620-6. (Pubitemid 41208625)
59. Hänel H, Weise A, Sun W, Pfützner JW, Thomé N, Pfützner A. Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol. 2008;2(3):478-81.
60. Asakura T. Comparison of the dosing accuracy of two insulin injection device. J Clin Res. 2005;8:33-40. (Pubitemid 43041653)
61. Penfornis A, Horvat K. Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther. 2008;10(5):359-62.
62. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin. 2008;24(5):1429-34. (Pubitemid 351741576)
63. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-74. (Pubitemid 46389914)
64. Weise A, Pfützner JW, Borig J, Pfützner AM, Safinowski M, Hänel H, Musholt PB, Pfützner A. Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol. 2009;3(1):149-53.
65. Friedrichs A. Dose accuracy of SoloSTAR and FlexPen as assessed in a clinical setting. Diabetes Technol Ther. 2009;11(9):609-13.
66. Ignaut DA, Opincar M, Lenox S. FlexPen and KwikPen prefilled insulin devices: a laboratory evaluation of ergonomic and injection force characteristics. J Diabetes Sci Technol. 2008;2(3):533-7.
67. Rissler J, Jørgensen C, Rye Hansen M, Hansen NA. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2217-22.
68. Toraishi K, Yuizono Y, Nakamura N, Kato S, Aoki T, Ashida K, Sako Y. Force requirements and insulin delivery profiles of four injection devices. Diabetes Technol Ther. 2005;7(4):629-35. (Pubitemid 41208627)
69. Asakura T, Jensen KH. Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol. 2009;3(2):312-9.
70. Reimer T, Hohberg C, Pfützner AH, Jørgensen C, Jensen KH, Pfützner A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008;30(12):2252-62.
71. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26(4):531-40. (Pubitemid 38586454)
72. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus FlexPen, Lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29(4):650-60. (Pubitemid 47016637)
73. Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol. 2008;2(6):1157-60.
74. Yakushiji F, Fujita H, Terayama Y, Yasuda M, Nagasawa K, Shimojo M, Taniguchi K, Fujiki K, Tomiyama J, Kinoshita H. The best insulin injection pen device for caregivers: results of injection trials using five insulin injection devices. Diabetes Technol Ther. 2010;12(2):143-8.